PCL, Inc.
- Jurisdiction
South Korea - ISIN
KR7241820000 (241820.KQ )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. Read full profile
Stock price
Fundamentals
- Net revenue
€2.07M - Gross margin
-241.1% - EBIT
-€13.53M - EBIT margin
-653.2% - Net income
-€28.74M - Net margin
-1,387.0%
Statement period: - (published )
Dividends
No dividend payouts